Dr. Carolina Haass-Koffler has received a R01 Award ($2.5M) from the NIH/NIAAA. A focus on alpha-1 blockade as a novel pharmacological treatment for alcohol use disorder (AUD). The goal of this study is to understand the role of stress in the development of AUD therapies that target noradrenergic blockade. This study proposes a 16-week, between-subject, double-blind, randomized clinical trial with doxazosin compared to placebo